Entering text into the input field will update the search result below

Iterum provides update on Type A meeting with the U.S. FDA on oral sulopenem NDA

Headquarters of US Food and Drug Administration (FDA)
Grandbrothers/iStock Editorial via Getty Images

  • Iterum Therapeutics (NASDAQ:ITRM) announced an update on the company's Type A meeting with the U.S. FDA related to the NDA for its sulopenem etzadroxil/probenecid (oral sulopenem), and provided an update on its cash position.

Recommended For You

More Trending News

About ITRM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ITRM--
Iterum Therapeutics plc